兔单克隆抗体GCET2在弥漫性大B细胞淋巴瘤诊断中的应用

[Application of rabbit monoclonal antibody GCET2 in diagnosis of diffuse large B cell lymphoma].

作者信息

Pan H Y, Zhang X X, Weng Y Y, Zhou R

机构信息

Department of Pathology and Pathophysiology, Institute of Pathology and Forensic Medicine, Zhejiang University School of Medicine, Hangzhou 310058, China.

出版信息

Zhonghua Bing Li Xue Za Zhi. 2016 Dec 8;45(12):844-849. doi: 10.3760/cma.j.issn.0529-5807.2016.12.006.

DOI:10.3760/cma.j.issn.0529-5807.2016.12.006

PMID:28056299

Abstract

To prepare a rabbit monoclonal antibody GCET2 and to investigate its diagnostic value in the workup of diffuse large B-cell lymphoma (DLBCL). GCET2 rabbit monoclonal antibody was developed by using RabMAb technology, and its specificity was confirmed by ELISA, Western blot, immunohistochemistry (IHC) and flow cytometry. A panel of immunomarkers including GCET2, CD10, bcl-6, MUM1, GCET1, FOXP1, Ki-67 and CMYC was evaluated in 81 cases of DLBCLs, 5 cases of follicular lymphomas (FL) and 2 cases of Burkitt's lymphomas. Rabbit monoclonal GCET2 antibody (clone EP316) was developed with specificity for normal germinal center B-cells (GCB) and GCB origined lymphomas. In 81 cases of DLBCL, the positive rate of GCET2 was 43.2%(35/81), which was significantly higher than that of other germinal center markers. Moreover, among 81 DLBCLs, the proportions of high CMYC expression in GCET2 negative and positive groups were 15.2% (7/46) and 2.8% (1/35), respectively. GCET2 is a sensitive immunohistochemical marker for GCB derived lymphomas. Combined with other biomarkers, it may improve the diagnostic sensitivity of GCB-DLBCL.

摘要

制备兔单克隆抗体GCET2，并研究其在弥漫性大B细胞淋巴瘤（DLBCL）诊断中的价值。采用RabMAb技术制备GCET2兔单克隆抗体，并通过酶联免疫吸附测定（ELISA）、蛋白质免疫印迹法（Western blot）、免疫组织化学（IHC）和流式细胞术确认其特异性。对81例DLBCL、5例滤泡性淋巴瘤（FL）和2例伯基特淋巴瘤患者评估了包括GCET2、CD10、bcl-6、MUM1、GCET1、FOXP1、Ki-67和CMYC在内的一组免疫标志物。制备了对正常生发中心B细胞（GCB）和起源于GCB的淋巴瘤具有特异性的兔单克隆GCET2抗体（克隆EP316）。在81例DLBCL中，GCET2阳性率为43.2%（35/81），显著高于其他生发中心标志物。此外，在81例DLBCL中，GCET2阴性和阳性组中CMYC高表达的比例分别为15.2%（7/46）和2.8%（1/35）。GCET2是GCB来源淋巴瘤的一种敏感免疫组织化学标志物。与其他生物标志物联合使用，可能提高GCB-DLBCL的诊断敏感性。